Lecap Asset Management Ltd. Has $2.36 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Lecap Asset Management Ltd. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 587.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 5,701 shares of the company’s stock after buying an additional 4,872 shares during the quarter. Lecap Asset Management Ltd.’s holdings in IDEXX Laboratories were worth $2,357,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in IDXX. International Assets Investment Management LLC increased its stake in shares of IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after buying an additional 527,460 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after purchasing an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd bought a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $113,104,000. Vontobel Holding Ltd. grew its holdings in IDEXX Laboratories by 3,325.0% in the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after purchasing an additional 213,731 shares during the period. Finally, Worldquant Millennium Advisors LLC grew its stake in shares of IDEXX Laboratories by 230.1% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock valued at $55,673,000 after buying an additional 76,809 shares during the period. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.18% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Down 1.7 %

NASDAQ:IDXX opened at $460.56 on Friday. The company has a market cap of $37.72 billion, a P/E ratio of 44.41, a P/E/G ratio of 3.64 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The stock’s fifty day moving average price is $426.81 and its two-hundred day moving average price is $453.62.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Bank of America boosted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday. Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Finally, Piper Sandler restated a “neutral” rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $524.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.